ATE424401T1 - Pyrrolderivate als hemmstoffe von cystein proteasen - Google Patents
Pyrrolderivate als hemmstoffe von cystein proteasenInfo
- Publication number
- ATE424401T1 ATE424401T1 AT03763972T AT03763972T ATE424401T1 AT E424401 T1 ATE424401 T1 AT E424401T1 AT 03763972 T AT03763972 T AT 03763972T AT 03763972 T AT03763972 T AT 03763972T AT E424401 T1 ATE424401 T1 AT E424401T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- sub
- inhibitors
- compounds
- diseases
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004171 Cathepsin K Human genes 0.000 abstract 1
- 108090000625 Cathepsin K Proteins 0.000 abstract 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008355 cartilage degradation Effects 0.000 abstract 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000024693 gingival disease Diseases 0.000 abstract 1
- 208000007565 gingivitis Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0216525A GB0216525D0 (en) | 2002-07-16 | 2002-07-16 | Biologically active compounds |
| GB0217239A GB0217239D0 (en) | 2002-07-25 | 2002-07-25 | Biologically active compounds |
| US41852402P | 2002-10-15 | 2002-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE424401T1 true ATE424401T1 (de) | 2009-03-15 |
Family
ID=30118828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03763972T ATE424401T1 (de) | 2002-07-16 | 2003-07-15 | Pyrrolderivate als hemmstoffe von cystein proteasen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060100431A1 (de) |
| EP (1) | EP1546150B1 (de) |
| JP (1) | JP2006504651A (de) |
| CN (1) | CN100354276C (de) |
| AT (1) | ATE424401T1 (de) |
| AU (1) | AU2003255711B2 (de) |
| BR (1) | BR0312662A (de) |
| CA (1) | CA2499465A1 (de) |
| DE (1) | DE60326473D1 (de) |
| IL (1) | IL165953A0 (de) |
| NZ (1) | NZ537853A (de) |
| WO (1) | WO2004007501A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2458919C2 (ru) | 2005-04-13 | 2012-08-20 | Астекс Терапьютикс Лимитед | ПРОИЗВОДНЫЕ ГИДРОКСИБЕНЗАМИДА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 |
| GB0513841D0 (en) * | 2005-07-07 | 2005-08-10 | Medivir Ab | Cysteine protease inhibitors |
| BRPI0614263A2 (pt) * | 2005-08-10 | 2011-03-22 | Amura Therapeutics Ltd | preparação de derivados de diazapetaleno através da epoxidação de diidropirróis |
| GB0517279D0 (en) * | 2005-08-23 | 2005-10-05 | Amura Therapeutics Ltd | Biologically active compounds |
| US7645773B2 (en) | 2006-01-18 | 2010-01-12 | Hoffmann-La Roche Inc. | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| WO2007105744A1 (ja) * | 2006-03-08 | 2007-09-20 | National University Corporation Kanazawa University | プルキンエ細胞指向性ウイルスベクター |
| EP2428205B1 (de) | 2006-03-16 | 2012-10-03 | Tris Pharma, Inc. | Modifizierte Freisetzungsformulierungen mit Arznei-Ion-Austausch-Harzkomplexen |
| GB0614042D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US8779132B2 (en) | 2006-10-12 | 2014-07-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2073802A1 (de) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmazeutische kombinationen |
| JP5528807B2 (ja) * | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| JP5587790B2 (ja) | 2008-01-09 | 2014-09-10 | アミュラ セラピューティクス リミティド | 化合物 |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US9409880B2 (en) | 2011-01-20 | 2016-08-09 | The Regents Of The University Of Colorado, A Body Corporate | Modulators of TLR3/dsRNA complex and uses thereof |
| AU2015223084B2 (en) | 2014-02-25 | 2019-11-07 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of complement mediated disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| EP3340983B1 (de) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl und heterocyclische verbindungen zur behandlung von immun- und entzündungserkrankungen |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| WO2017035355A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| IL303696B2 (en) | 2017-03-01 | 2025-02-01 | Achillion Pharmaceuticals Inc | Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders |
| EP3589287B1 (de) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Makrocyclische verbindungen zur behandlung von medizinischen erkrankungen |
| US20190038623A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
| BR112021004263A2 (pt) | 2018-09-06 | 2021-05-25 | Achillion Pharmaceuticals, Inc. | formas mórficas de danicopano |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| WO2020069024A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| CN113195472A (zh) | 2018-12-17 | 2021-07-30 | 艾其林医药公司 | 用于治疗补体介导的病症的靶向给药 |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| WO2023081666A1 (en) * | 2021-11-02 | 2023-05-11 | Aria Pharmaceuticals, Inc. | Compounds as ccr2 modulators |
| WO2023081662A1 (en) * | 2021-11-02 | 2023-05-11 | Aria Pharmaceuticals, Inc. | Bicyclic derivatives as ccr2 modulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013079A1 (es) * | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
| GB9911417D0 (en) * | 1999-05-18 | 1999-07-14 | Peptide Therapeutics Ltd | Furanone derivatives as inhibitors of cathepsin s |
| MXPA03006224A (es) * | 2001-01-17 | 2004-10-15 | Amura Therapeutics Ltd | Inhibidores de cruzipaina y otras proteasas de cisteina. |
-
2003
- 2003-07-15 AT AT03763972T patent/ATE424401T1/de not_active IP Right Cessation
- 2003-07-15 JP JP2004520827A patent/JP2006504651A/ja active Pending
- 2003-07-15 AU AU2003255711A patent/AU2003255711B2/en not_active Expired - Fee Related
- 2003-07-15 NZ NZ537853A patent/NZ537853A/xx unknown
- 2003-07-15 EP EP03763972A patent/EP1546150B1/de not_active Expired - Lifetime
- 2003-07-15 CA CA002499465A patent/CA2499465A1/en not_active Abandoned
- 2003-07-15 US US10/521,354 patent/US20060100431A1/en not_active Abandoned
- 2003-07-15 WO PCT/GB2003/002957 patent/WO2004007501A1/en not_active Ceased
- 2003-07-15 CN CNB038219255A patent/CN100354276C/zh not_active Expired - Fee Related
- 2003-07-15 DE DE60326473T patent/DE60326473D1/de not_active Expired - Lifetime
- 2003-07-15 BR BR0312662-5A patent/BR0312662A/pt not_active IP Right Cessation
-
2004
- 2004-12-23 IL IL16595304A patent/IL165953A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003255711A1 (en) | 2004-02-02 |
| IL165953A0 (en) | 2006-01-15 |
| HK1084115A1 (zh) | 2006-07-21 |
| EP1546150B1 (de) | 2009-03-04 |
| DE60326473D1 (en) | 2009-04-16 |
| AU2003255711B2 (en) | 2008-11-13 |
| CN1681817A (zh) | 2005-10-12 |
| CA2499465A1 (en) | 2004-01-22 |
| US20060100431A1 (en) | 2006-05-11 |
| WO2004007501A1 (en) | 2004-01-22 |
| EP1546150A1 (de) | 2005-06-29 |
| CN100354276C (zh) | 2007-12-12 |
| NZ537853A (en) | 2007-02-23 |
| BR0312662A (pt) | 2005-05-03 |
| JP2006504651A (ja) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE424401T1 (de) | Pyrrolderivate als hemmstoffe von cystein proteasen | |
| ATE411294T1 (de) | 4-amino-azepan-3-on-derivate als protease- inhibitors | |
| NO20024528D0 (no) | Proteaseinhibitorer | |
| DE60207652D1 (de) | Durch Säuregruppen disubstitierte Heteroaryl-Derivate und ihre Verwendung als Matrix Metalloproteinas Inhibitoren | |
| NO20051223L (no) | Oksadiazoler som modulatorer av metabotropisk glutamat reseptor-5. | |
| ATE427932T1 (de) | 11beta-hsd1-inhibitoren | |
| HUP0100669A2 (hu) | Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| EA200200940A1 (ru) | Производные азетидина, способ их получения и содержащие их фармацевтические композиции | |
| MXPA03006224A (es) | Inhibidores de cruzipaina y otras proteasas de cisteina. | |
| DE602004014347D1 (de) | Chinazolin-derivate als tgf-beta-inhibitoren | |
| ATE346857T1 (de) | Kombinatorische herstellung von bibliotheken aus makrozyklischen verbindungen zur entdeckung von pharmazeutischen wirkstoffen | |
| NO995268L (no) | Proteaseinhibitorer | |
| EA200400708A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
| DE602004029355D1 (de) | Sulfopyrrolderivate | |
| MXPA02012442A (es) | Inhibidores de proteasa. | |
| DE60232289D1 (de) | Photopolymerisierbare Verbindungen | |
| DK1525188T3 (da) | Hidtil ukendte derivater af 4,4-dithiobis-(3-aminobutan-1-sulfonater) og sammensætninger, der indeholder dem | |
| HK1042695A1 (zh) | 蛋白酶抑制剂 | |
| HRP20020440B1 (en) | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | |
| HK1041690A1 (zh) | 蛋白酶抑制剂 | |
| WO2002057246A3 (en) | Inhibitors of cruzipain and other cysteine proteases | |
| UY26088A1 (es) | Inhibidores de proteasas | |
| EA200400409A1 (ru) | Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их | |
| Ye et al. | Synthesis and biological evaluation of menthol-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | |
| ATE472326T1 (de) | Neue zyklische harnstoffe als inhibitoren von metalloproteasen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |